The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AR-1H2667     8-[2-[[(1S)-1-ethoxycarbonyl- 3-phenyl...

Synonyms: AC1L3MP4, AC1Q63IP, NCGC00182545-01
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Sch 33844

  • In conclusion, a significant regression of left ventricular hypertrophy was obtained after 1 year of treatment with spirapril and isradipine, whereas a similar reduction in medial thickness relative to lumen diameter of subcutaneous small arteries could not be observed in all patients [1].
  • Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension [2].
  • RESULTS: The pressure-diameter curve of the placebo group was shifted to the left compared to the curves of the control and spirapril groups, showing that renovascular hypertension was associated with isobaric reduction of aortic diameter [3].
  • Treatment with spirapril (2-2.5 or zofenopril (12-15 added to the drinking water was started immediately after myocardial infarction or sham operation and continued for six weeks [4].
  • Systemic, pulmonary, brachial, renal and hepato-splanchnic hemodynamic effects of spirapril in severe congestive heart failure [5].

Psychiatry related information on Sch 33844


High impact information on Sch 33844


Chemical compound and disease context of Sch 33844


Biological context of Sch 33844


Anatomical context of Sch 33844


Associations of Sch 33844 with other chemical compounds


Gene context of Sch 33844


Analytical, diagnostic and therapeutic context of Sch 33844

  • The stiffness index beta was higher (p < 0.05) in the placebo group [0.605(SD 0.304) mm-1] than in either the control group [0.362(0.126) mm-1] or the spirapril group [0.348(0.083) mm-1], suggesting that renovascular hypertension was associated with aortic stiffening [3].
  • In crossover design, each also received spirapril or matching placebo capsules during weeks 1 and 2, or 4 and 5 [11].
  • All three treatment modalities decreased significantly LV mass index by an average of 10%, although the combination had the greatest blood pressure-lowering effect and spirapril had the least, as assessed by office resting pressures, ambulatory monitoring, and isometric grip testing [24].
  • Possible advantages of spirapril compared to other ACE inhibitors are the dual mechanism of elimination, the lack of need for dose titration and a low incidence of cough [25].
  • There was a statistically significant reduction of mortality in the pooled spirapril groups compared with placebo, and a trend for reduction of serious cardiovascular adverse events as well as duration of hospitalization [26].


  1. Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries. Thürmann, P.A., Stephens, N., Heagerty, A.M., Kenedi, P., Weidinger, G., Rietbrock, N. Hypertension (1996) [Pubmed]
  2. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Noble, S., Sorkin, E.M. Drugs (1995) [Pubmed]
  3. Preventive effect of chronic converting enzyme inhibition on aortic stiffening induced by renovascular hypertension in conscious dogs. Fischer, E.I., Levenson, J., Barra, J.G., Armentano, R.L., Pichel, R.H., Simon, A. Cardiovasc. Res. (1993) [Pubmed]
  4. Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril. van Wijngaarden, J., Pinto, Y.M., van Gilst, W.H., de Graeff, P.A., de Langen, C.D., Wesseling, H. Cardiovasc. Res. (1991) [Pubmed]
  5. Systemic, pulmonary, brachial, renal and hepato-splanchnic hemodynamic effects of spirapril in severe congestive heart failure. Bellissant, E., Annane, D., Pussard, E., Thuillez, C., Giudicelli, J.F. Fundamental & clinical pharmacology. (1996) [Pubmed]
  6. Central angiotensin II controls alcohol consumption via its AT1 receptor. Maul, B., Krause, W., Pankow, K., Becker, M., Gembardt, F., Alenina, N., Walther, T., Bader, M., Siems, W.E. FASEB J. (2005) [Pubmed]
  7. Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure. van den Broek, S.A., de Graeff, P.A., van Veldhuisen, D.J., van Gilst, W.H., Hillege, H., Wesseling, H., Lie, K.I. J. Card. Fail. (1997) [Pubmed]
  8. Effects of spirapril and captopril on regional blood flow in chronic congestive heart failure: a comparison between a short- and a long-acting angiotensin-converting enzyme inhibitor. van den Broek, S.A., de Graeff, P.A., Smit, A.J., Girbes, A.R., Journée, n.u.l.l., van Gilst, W.H., Hillege, H., van Veldhuisen, D.J., Wesseling, H., Lie, K.I. J. Cardiovasc. Pharmacol. (1995) [Pubmed]
  9. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? van den Meiracker, A.H., Man in 't Veld, A.J., Admiraal, P.J., Ritsema van Eck, H.J., Boomsma, F., Derkx, F.H., Schalekamp, M.A. J. Hypertens. (1992) [Pubmed]
  10. Angiotensin converting enzyme inhibitors: spirapril and related compounds. Smith, E.M., Swiss, G.F., Neustadt, B.R., McNamara, P., Gold, E.H., Sybertz, E.J., Baum, T. J. Med. Chem. (1989) [Pubmed]
  11. Digoxin pharmacokinetics and spirapril, a new ace inhibitor. Johnson, B.F., Wilson, J., Johnson, J., Flemming, J. Journal of clinical pharmacology. (1991) [Pubmed]
  12. Short- and long-term effects of spirapril on renal hemodynamics in patients with essential hypertension. Reams, G.P., Lau, A., Knaus, V., Bauer, J.H. Journal of clinical pharmacology. (1993) [Pubmed]
  13. Pathogenetic role of vascular angiotensin-converting enzyme in the spontaneously hypertensive rat. Okunishi, H., Kawamoto, T., Kurobe, Y., Oka, Y., Ishii, K., Tanaka, T., Miyazaki, M. Clin. Exp. Pharmacol. Physiol. (1991) [Pubmed]
  14. Angiotensin-converting enzyme inhibition with spirapril in patients with coronary artery disease. Thürmann, P., Rietbrock, N. Blood pressure. Supplement. (1994) [Pubmed]
  15. Spirapril and cilazapril inhibit neointimal lesion development but cause no detectable inhibition of lumen narrowing after carotid artery balloon catheter injury in the rat. Cook, N.S., Zerwes, H.G., Pally, C., Rudin, M., Hof, R.P. Blood Press. (1993) [Pubmed]
  16. Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing. Pelttari, L.H., Hietanen, E.K., Salo, T.T., Kataja, M.J., Kantola, I.M. Am. J. Hypertens. (1998) [Pubmed]
  17. Radioimmunoassays for spirapril and its active metabolite spiraprilate: performance and application. Hossein-Nia, M., Surve, A.H., Weglein, R., Gerbeau, C., Holt, D.W. Therapeutic drug monitoring. (1992) [Pubmed]
  18. Isradipine in the treatment of mild-to-moderate hypertension. The Austrian Multicenter Isradipine cum Spirapril Study (AMICUS). Magometschnigg, D. Am. J. Hypertens. (1993) [Pubmed]
  19. Metabolic effects of spirapril and atenolol: results from a randomized, long-term study. Hakamäki, T., Lehtonen, A. International journal of clinical pharmacology and therapeutics. (1997) [Pubmed]
  20. ACE inhibition in chronic renal failure and in the treatment of diabetic nephropathy: focus on spirapril. Jardine, A.G., Elliott, H.L. J. Cardiovasc. Pharmacol. (1999) [Pubmed]
  21. Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Schindler, R., Dinarello, C.A., Koch, K.M. Cytokine (1995) [Pubmed]
  22. Effect of spirapril and hydrochlorothiazide on platelet function and euglobulin clot lysis time in patients with mild hypertension. Gleerup, G., Petersen, J.R., Mehlsen, J., Winther, K. Angiology. (1996) [Pubmed]
  23. Discrepancy between renin mRNA and plasma renin level in angiotensin-converting enzyme inhibitor-treated rats. Morishita, R., Higaki, J., Nagano, M., Nakamura, F., Tomita, N., Zhao, Y., Mikami, H., Miyazaki, M., Ogihara, T. Clin. Exp. Pharmacol. Physiol. (1993) [Pubmed]
  24. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. Manolis, A.J., Beldekos, D., Handanis, S., Haralabidis, G., Hatzissavas, J., Foussas, S., Cokkinos, D.V., Bresnahan, M., Gavras, I., Gavras, H. Am. J. Hypertens. (1998) [Pubmed]
  25. Efficacy and safety of spirapril in mild-to-moderate hypertension. Hayduk, K., Kraul, H. J. Cardiovasc. Pharmacol. (1999) [Pubmed]
  26. Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure. Widimský, J., Kremer, H.J., Jerie, P., Uhlír, O. Eur. J. Clin. Pharmacol. (1995) [Pubmed]
WikiGenes - Universities